As the novel Coronavirus tears through most continents on the planet, one thing that’s become increasingly clear is that we have dropped the ball on hygiene. The disease is transmitted through droplets expelled from an infected person due to coughing or sneezing, and just a few months since it first appeared in Asia, it has caused quite some damage. More than 400,000 have been infected, and governments are imploring residents to practice social distancing coupled with constant and thorough hand washing to curb its spread.
The World Health Organization (WHO) recently announced that antibiotic-resistant bacteria may claim over 50 million lives by 2050, and this brings into question the availability and viability of alternative antibacterial options like cannabis.
Although the plant is still illegal at the federal level, there have been several studies into its medical capabilities. It produces a group of unique chemicals called cannabinoids, and they hold most of its medical potential. The most prevalent ones are THC, the psychoactive chemical responsible for marijuana’s high and cannabidiol (CBD), which is probably the most medically potent cannabinoid we know of at the moment.
Previous studies have found cannabis to be especially good at clearing bacteria, with a January 2020 study published in the Cureus Journal finding that it cleaned plaque better than over the counter hygiene products.
“Cannabinoids have the potential to be used as an effective antibacterial agent against dental plaque-associated bacteria. Moreover, it provides a safer alternative to synthetic antibiotics to reduce the development of drug resistance,” the researchers wrote.
Another study by the University of Queensland’s Institute for Molecular Bioscience’s Center for Superbug Solutions in Australia into cannabis’ antiseptic properties found that it was not only a potent anti-inflammatory but also has potential as an antibiotic. Researchers concluded that “cannabidiol was remarkably effective at killing a wide range of Gram-positive bacteria, including bacteria that have become resistant to other antibiotics and did not lose effectiveness after extended treatment.”
Brandon Novy, a microbiology researcher at Reed College in Portland also presented a similar CBD focused study that found cannabidiol has the potential to fight gram-negative infections. Given WHO’s prediction of antibiotic-resistant bacteria, he believes these findings warrant more attention.
“Given cannabidiol’s documented anti-inflammatory effects, existing safety data in humans and potential for varied delivery routes, it is a promising new antibiotic worth further investigation. The combination of inherent antimicrobial activity and potential to reduce damage caused by the inflammatory response to infections is particularly effective,” says Dr. Mark Blaskovich, lead researcher of the University of Queensland’s study.
It is widely believed by analysts that industry players like Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) aren’t surprised by the research indicating cannabis’ antimicrobial properties, and more is yet to be discovered about this versatile plant.
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Do you have a questions or are you interested in working with CNW420? Ask our Editor
CNW420 is part of the InvestorBrandNetwork.